Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623191 | 0.95 | PLA2G2C (0.33) | MMP1MMP2MMP3SMPD1PLA2G2C | |
| Hydrochloric Acid SCHEMBL4879969 | 0.93 | PLA2G2C (0.32) | MMP1MMP2MMP3PLA2G2CTRPM8 | |
| SCHEMBL1039032 | 0.89 | PPARD (0.32) | MMP1MMP2MMP3PPARD | |
| SCHEMBL779433 | 0.85 | TRPM8 (0.45) | SMPD1TRPM8 | |
| SCHEMBL4158403 | 0.83 | PPARD (0.39) | MMP1MMP2MMP3SMPD1PLA2G2C | |
| SCHEMBL16427895 | 0.81 | LPAR3 (0.50) | SMPD1TRPM8 | |
| SCHEMBL11649168 | 0.81 | LPAR3 (0.50) | SMPD1TRPM8 | |
| SCHEMBL14890431 | 0.81 | LPAR3 (0.50) | SMPD1TRPM8 | |
| SCHEMBL864318 | 0.81 | CYP1A2 (0.47) | PLA2G2C | |
| SCHEMBL10799957 | 0.81 | LPAR3 (0.50) | SMPD1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567513-A | Self-assembled monolayer hole transport material containing bisphosphonic acid terminal group, preparation method and application | 南开大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| EP-2880028-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014022528-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019186-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| US-7795255-B2 | Rigidified compounds for modulating heparanase activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-09-14 | — | — | US | disclosed |
| US-7728014-B2 | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity | ALLERGAN, INC. | 2010-06-01 | — | — | US | disclosed |
| EP-1418902-A4 | NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DYSMENORRHOEA AND MENSTRUAL SIDE EFFECTS: THE USE OF PHOSPHOLIPASE INHIBITORS | UNIV QUEENSLAND (AU) | 2007-06-13 | — | — | EP | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006072953-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20040247639-A1 | Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-12-09 | — | — | US | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1418902-A1 | NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DYSMENORRHOEA AND MENSTRUAL SIDE EFFECTS: THE USE OF PHOSPHOLIPASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-05-19 | — | — | EP | disclosed |
| WO-2002005808-A1 | NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DYSMENORRHOEA AND MENSTRUAL SIDE EFFECTS: THE USE OF PHOSPHOLIPASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-24 | — | — | WO | disclosed |
| US-4026709-A | Color photographic recording material | CIBA-GEIGY AG (CH) | 1977-05-31 | — | — | US | disclosed |
| US-3984432-A | PHOSPHONIC ACID AND PHOSPHORIC ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | MMP1 4760/4885MMP2 4000/4885MMP3 4204/4885 |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | MMP1 4760/4885MMP2 4000/4885MMP3 4204/4885 |
| US-20040247639-A1 | Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors | PLA2G12A, PLA2G1B, PLA2G2E | MMP1 737/4885MMP2 328/4885MMP3 150/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | MMP1 308/4885MMP2 1015/4885MMP3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.